Cargando…

Imprinted Genes and Multiple Sclerosis: What Do We Know?

Multiple sclerosis (MS) is a chronic autoimmune neurodegenerative disease of the central nervous system that arises from interplay between non-genetic and genetic risk factors. The epigenetics functions as a link between these factors, affecting gene expression in response to external influence, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baulina, Natalia, Kiselev, Ivan, Favorova, Olga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866243/ https://www.ncbi.nlm.nih.gov/pubmed/33572862 http://dx.doi.org/10.3390/ijms22031346

Ejemplares similares

MiRNAs from DLK1-DIO3 Imprinted Locus at 14q32 are Associated with Multiple Sclerosis: Gender-Specific Expression and Regulation of Receptor Tyrosine Kinases Signaling
por: Baulina, Natalia, et al.
Publicado: (2019)

Variants of MicroRNA Genes: Gender-Specific Associations with Multiple Sclerosis Risk and Severity
por: Kiselev, Ivan, et al.
Publicado: (2015)

Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
por: Boziki, Marina Kleopatra, et al.
Publicado: (2020)

From miRNA Target Gene Network to miRNA Function: miR-375 Might Regulate Apoptosis and Actin Dynamics in the Heart Muscle via Rho-GTPases-Dependent Pathways
por: Osmak, German, et al.
Publicado: (2020)

MiRNA-Regulated Pathways for Hypertrophic Cardiomyopathy: Network-Based Approach to Insight into Pathogenesis
por: Osmak, German, et al.
Publicado: (2021)

What do we know about the role of lncRNAs in multiple sclerosis?
por: Nociti, Viviana, et al.
Publicado: (2021)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

Circulating miR-499a-5p Is a Potential Biomarker of MYH7—Associated Hypertrophic Cardiomyopathy
por: Baulina, Natalia, et al.
Publicado: (2022)

Vaginal Aging—What We Know and What We Do Not Know
por: Szymański, Jacek K., et al.
Publicado: (2021)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

Biogenic Silver Nanoparticles: What We Know and What Do We Need to Know?
por: Rai, Mahendra, et al.
Publicado: (2021)

Maternal Multiple Sclerosis and Offspring’s Cognitive and Behavioral Development: What Do We Know until Now?
por: Siracusano, Martina, et al.
Publicado: (2022)

What do we know and when do we know it?
por: Nicholls, Anthony
Publicado: (2008)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Anxiety and Depression: What Do We Know of Neuropeptides?
por: Kupcova, Ida, et al.
Publicado: (2022)

Novel Genes Involved in Hypertrophic Cardiomyopathy: Data of Transcriptome and Methylome Profiling
por: Kiselev, Ivan, et al.
Publicado: (2022)

Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
por: Gershman, Boris, et al.
Publicado: (2015)

Cerebrospinal fluid circulation: What do we know and how do we know it?
por: Khasawneh, Ahmad H, et al.
Publicado: (2018)

Mechanisms of atrial fibrillation in athletes: what we know and what we do not know
por: Guasch, E., et al.
Publicado: (2018)

Shared genetic architecture of COVID-19 and Alzheimer’s disease
por: Matveeva, Natalia, et al.
Publicado: (2023)

The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know
por: Goldstein, David S.
Publicado: (2021)

Health Statistics in Australia: What We Know and Do Not Know
por: Madden, Richard, et al.
Publicado: (2022)

Equine Crofton Weed (Ageratina spp.) Pneumotoxicity: What Do We Know and What Do We Need to Know?
por: Shapter, Frances Marie, et al.
Publicado: (2023)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

Collapsing the list of myocardial infarction-related differentially expressed genes into a diagnostic signature
por: Osmak, German, et al.
Publicado: (2020)

Plastic Interactions with Pollutants and Consequences to Aquatic Ecosystems: What We Know and What We Do Not Know
por: Cássio, Fernanda, et al.
Publicado: (2022)

Chikungunya and diabetes, what do we know?
por: de Almeida Barreto, Francisca Kalline, et al.
Publicado: (2018)

Nutrition and Sarcopenia—What Do We Know?
por: Ganapathy, Aravinda, et al.
Publicado: (2020)

What do we know about pseudodementia?
por: Mouta, Salomé, et al.
Publicado: (2023)

The risk of viral transmission in feed: What do we know, what do we do?
por: Dee, Scott A., et al.
Publicado: (2020)

Transmission of Ebola Viruses: What We Know and What We Do Not Know
por: Osterholm, Michael T., et al.
Publicado: (2015)

Arrhythmic Burden in Cardiac Amyloidosis: What We Know and What We Do Not
por: Argirò, Alessia, et al.
Publicado: (2022)

Dysfunctional breathing: what do we know?
por: Vidotto, Laís Silva, et al.
Publicado: (2019)

Gullo’s syndrome – what do we know?
por: Rycyk, Anna, et al.
Publicado: (2020)

The origin of life: what we know, what we can know and what we will never know
por: Pross, Addy, et al.
Publicado: (2013)

On Contagion: What Do We Know Regarding It
Publicado: (1877)

Evolutionary ecology of Chagas disease; what do we know and what do we need?
por: Flores‐Ferrer, Alheli, et al.
Publicado: (2017)

What We Know and Do Not Know about Sex and Cardiac Disease
por: Konhilas, John P.
Publicado: (2010)

Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?
por: Abdulameer, Shaymaa Abdalwahed, et al.
Publicado: (2012)

COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”
por: Mansoor, Salman, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2l04kan5ci3os2242l3s0lf5g8